Eli Lilly reports positive data in Phase 3 trial of weight-loss drug as treatment for sleep apnea

Zepbound reduced apnea effect by up to 63% and achieved about 20% weight loss after a year.

Previous post Travelers’ stock drops after profit misses expectation, as catastrophe losses increased
Next post Why the bond market still holds the cards as Fed walks back its pivot talk